Practice patterns and resources are not well established for patients with less common cancers such as myelofibrosis. Community cancer programs may be challenged to keep up with evolving treatments, new anti-cancer medications, and the availability of clinical trials for patients with myelofibrosis.
The ACCC myelofibrosis survey is now closed. Thank you to all survey respondents.
Analysis of survey responses is currently underway. Look for a summary of survey results coming soon.